New drug cuts heart failure risk in miceNovember 19th, 2008 - 12:46 pm ICT by ANI
London, Nov 19 (ANI): Scientists at Miragen Therapeutics in Boulder, Colorado have found that a new drug seems to protect mice from heart failure even when enormous pressure is placed on their hearts.
According to the researchers, if the results can be replicated in humans, it could help millions of people avoid some of the long-term consequences of a heart attack.
The new drug targets a micro RNA - a molecule that inhibits the expression of a network of genes.
Recently, the researchers found that a micro RNA called miR-208 is implicated in heart failure and that mice engineered to lack the gene for miR-208 are protected against heart failure.
Therefore, William Marshall at Miragen Therapeutics in Boulder, Colorado, and his colleagues developed an injectable antagomir - a string of nucleic acids designed to bind to miR-208 and block its action.
In the study, they injected the antagomir into the hearts of healthy mice then severely stressed them by tying a band around the major blood vessel that carries blood away from the heart.
The researchers found that blocking the inhibitory effects of miR-208 caused an increase in gene expression and the hearts did not develop the usual signs of heart failure, which include enlarged muscle cells and a switch towards a fetal form of heart protein that makes the heart beat less efficiently.
“This is the first time that a drug has been able to reverse the switch [to the fetal protein] and take it back to the [adult] form,” New Scientist quoted Marshall, as saying
Marshall is now trying to replicate the results in sheep and hopes that the drug could eventually be injected into human hearts, perhaps alongside surgery after a heart attack in order to protect people against heart failure.
Hasse Bronnum, a researcher in molecular cardiology at the University of Southern Denmark in Odense, said: “If the data are reproducible in humans, there will be vast clinical potential for applying miR-208 antagonists in the treatment of a number of cardiac diseases.
However, he cautions that Marshall has not yet shown that the antagomir is protective after heart attacks.
The study is published in the journal Science. (ANI)
- MicroRNAs could increase amputation risk in diabetics - Jan 13, 2011
- Lung cancer culprit could offer therapeutic target - Sep 14, 2010
- RNA-based drugs may prevent premature labour - Nov 16, 2010
- Potential genetic target for heart disease discovered - Nov 18, 2010
- Function of novel molecule that underlies human deafness revealed - Jan 22, 2011
- New discovery may lead to better cholesterol drugs - Oct 06, 2010
- Key step in body's ability to make red blood cells found - Aug 01, 2010
- New discovery shows promise against pancreatic cancer - Dec 16, 2010
- Micro-RNA that regulates insulin in obesity identified - Apr 01, 2011
- Scientists convert skin cells to stem cells more effieciently - Feb 03, 2011
- Boffins identify 'gas pedal', 'brake' for uncontrolled cell growth - Aug 02, 2010
- Molecule engineered to attack HIV shows positive results - Jan 20, 2011
- Stem cell patch may improve function after heart attack - Nov 16, 2010
- Body's own molecular protection against arthritis discovered - May 19, 2010
- Micro-RNA decides malignancy of lung cancer - Sep 09, 2010
Tags: adult form, antagomir, blood vessel, boulder colorado, drug targets, gene expression, heart attack, heart failure, heart failure risk, human hearts, inhibitory effects, major blood, molecular cardiology, muscle cells, new scientist, nucleic acids, signs of heart failure, term consequences, university of southern denmark, william marshall